Christopher Benedict, Ph.D.

Christopher Benedict, Ph.D.


Beyond TNF: A Newly Discovered Cytokine may provide new target for RA Therapy
Christopher Benedict, Ph.D.

La Jolla Institute for Allergy and Immunology
San Diego, CA
Analyzing the contribution of the LIGHT-HVEM-BTLA system in autoimmune arthritis

Tumor necrosis factor (TNF) is a cytokine produced by the body’s immune cells that fuels the process of inflammation in rheumatoid arthritis (RA). Blocking TNF is the best current treatment for RA. Dr. Benedict is studying a newly discovered cytokine network that is a close relative of TNF and may contribute to the initiation and/or severity of RA. Using mouse models, he hopes to generate information about neutralizing this new network that could lead to new clinical treatments for RA.

Dr. Benedict is this year’s Eng Tan Scholar, so honored for his innovative approach to studying inflammatory arthritis.

Article Author
Arthritis National Research Foundation

The Arthritis National Research Foundation's mission is to provide initial research funding to brilliant, investigative scientists with new ideas to cure arthritis and related autoimmune diseases. Writing articles about the patients affected and the science being done to find a cure shows why we need to come together to #CureArthritis!

No Comments

Sorry, the comment form is closed at this time.